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New test is provided
at no cost to parents

Texas Outreach Program offers
neuroblastoma saeening in infants
Cancer Detection

Joann L. Ater, an assistant
professor of pediatrics in
the Department of
Pediatrics, is the director of
the Neuroblastoma
Screening Program, one of
10 projects under the
auspices of the Texas
Outreach Program

Neuroblastoma is an aggressive cancer of the peripheral nervous system that is most commonly characterized by tumors in the abdomen, along the spine,
on the skull, and behind the eyes. It affects one in
every 6,000 children under five years of age and is the
second most common solid tumor in children. like
many cancers, neuroblastoma is much more likely to
be cured if detected early: although the cure rate is
only 20% to 40% in children whose disease is diagnosed after the first birthday, it is over 80% in children
less than one year of age. Unfortunately, because the
disease is not usually detectable that early through
normal well-baby physical examinations, few neuroblastomas are diagnosed in time to take advantage of
these excellent odds. A new statewide screening program, however, may soon improve Texas children's
chances of cure.

The test is inexpensive, easy to perform, and
accurate
Physicians at The University of Texas M. D. Anderson Cancer Center are taking advantage of a new test
that can cheaply and accurately detect the levels of two
catecholamine metabolites, homovanillic acid (HVA)
and vanillymandelic acid (VMA), in the urine. Elevated levels of these substances may indicate several
different kinds of tumors, but none of these is known
to occur in young children except neuroblastoma, essentially making the test specific for neuroblastoma in
ts un er one year o . e test,
uses monoclonal antibodies to identify HVA and VMA, is not
easily contaminated, requires simple saturation of a
filter paper with urine, and can be processed quickly in
large numbers. The older tests were more laborious,
could be contaminated by several normal dietary substances (such as vanilla) and medications, and in some
cases required 24-hour urine collection.
The recently introduced program will screen six- to
nine-month-old infants through much of the state.

The program, under the direction of Joann L. Ater,
M.D ., Department of Pediatrics, is one of 10 projects
that compose the Texas Outreach Program, a cancer
prevention initiative designed to provide new and expanded cancer screening and detection services in communities across the state. The overall goal of Texas
Outreach is to make cancer resources more accessible
to all Texans, especially those in rural and economically depressed areas and areas with higher-than-normal cancer incidence. The program attempts to enlist
primary care physicians, nurses, allied health workers,
and lay persons in practical cancer prevention and
early detection programs. It is to be paid for not by
state funds but by up to $15 million in fees earned by
the physicians of M. D. Anderson.

Informal consortium established
The neuroblastoma screening program began when
an informal consortium of Texas pediatric oncologists
recognized the critical need for early detection of the
disease in young children. "Our immediate goal," Ater
said, "is to detect neuroblastoma at a younger age
and, therefore, reduce the population-based mortality
rate from the disease. We want children who test
positive to be seen by a pediatric oncologist before
their first birthday."
Oncologists who volunteered for the neuroblastoma
screening program became "nodes" in a statewide
network of screening sites. The network comprises
ma1or me opo
areas in e s e, a o o :i------counties, and accounts for nearly two-thirds of all the
births in Texas, or about 300,000 per year. The actual
screening began in August 1992. Names of newborn
infants in the 32 counties were obtained from a Texas
Department of Health data base. A test kit was sent
to the parents of each child, along with a bilingual
brochure explaining the purpose of the test and
giving instructions for the collection and mailing
of the sample.
continued on page 2
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--we want children who test positive
to be seen by a pediatric oncologist
before their first birthda~

The procedure consists in saturating .a filter paper
with the child's urine. The filter is dried and placed in
a preaddressed, stamped plastic mailer. A technician
at M. D. Anderson processes the samples, and parents of children whose tests are positive are contacted, usually within about a month. (Parents who
do not receive a response can assume that the test
was negative, although they are given a telephone
number they may call to get their child's results.)
When the test is positive or inconclusive, the parents
receive a second kit. If the child again tests positive,
the parents are asked to take their child to the family
doctor or pediatrician (who is named on the form
returned with the specimen) for further evaluation.
At the same time, Ater or one of the other physicians
involved in the project contacts that physician with
information on the test and the disease and provides
guidelines for evaluating the child. If the follow-up
liquid urine sample is also positive, the physician is
asked to refer the child to one of several pediatric
oncologists in their area who have agreed to see
these children.

Texas primary care physicians are key to
program's success
Informed primary care physicians are a cornerstone
of the project. Because any primary care physician in
Texas may see an infant who has had the test, nearly
10,000 physicians in the state received a mailing in
the summer of 1992 outlining the importance of
early detection, the details of the screening project,
and the physician's role in it. A second mailing is
planned for this winter. Large, colorful posters explaining the program that are suitable for posting in
waitmg rooms ave
distributed.
Of the 39,000 kits that have been mailed since
August, about 3,000 have been returned. Three children have tested positive twice, but neuroblastoma
has not been confinned in any of them. Ater characterized compliance with the screening program as
"improving," although the initial response rate was
very poor. One element of the project is a study of
why parents would resist having their child tested,
even though the test has been made both conve-
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nient and free. Statewide media releases have been
targeted at educating the public about neuroblastoma
and the need for screening.

Testing not yet mandatory
Such directed and repeated efforts to encourage
testing are necessary because the project depends on
voluntaty compliance. Archie Bleyer, M .D., however,
feels that the benefits of testing and the incidence of
the disease will eventually call for mandatory testing,
as is the case for phenylketonuria and galactosemiatwo conditions that are rarer than neuroblastoma: ''We
see our screening program as a prototype or feasibility
study for developing a proposal that may make neuroblastoma screening mandatory in Texas," said Bleyer,
who is head of the Division of Pediatrics at M. D.
Anderson and chairman of the group that oversees
the Texas Outreach Program. "Neuroblastoma screening of infants has been mandatory in Japan since 1985,
and their data have shown a reduction in the death
rate from the disease. An ongoing study in Quebec
has been sufficiently rewarding that the province is
considering requiring it. In the U.S., M aryland is also
beginning neuroblastoma screening," he said. Screening programs are also in place in Australia, Ausni.a,
Brazil, England, France, Germany, and Norway.
Whether neuroblastoma screening becomes state law
or not, the program's directive is to identify children
with the disease and get them the medical attention
they need. M. D. Anderson has devoted substantial
resources to achieving this goal, but the program's
success will depend upon the support provided by
primary care physicians. ■
- KATHRYN L. HALE
Physicians who desire additional information may
write Dr. Ater, Department of Pediatrics, Box 84,
The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Blvd., Houston, Texas,
77030, or call (713) 794-4620.
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Sensitivity to carcinogens varies
in the human population

Clinicians' ability to predict
cancer risk may lie in new assay
If not for theft and revolution, T. C. Hsu, Ph.D.,
might have been a poet in mainland China instead of
an eminent scientist. Hsu professes to have been a
"not too diligent student," more interested in poetry
and literature than in science, but his interests were
redirected when, on a school day in the 1930s, Hsu
opened his desk to learn that someone had stolen his
prized stamp collection. He was heartbroken, so he
vowed to collect something no one else would want:
bugs. His interest in insects led to an interest in science, and in 1948 Hsu found himself in Austin, pursuing a Ph.D. in genetics at The University of Texas.
H e intended to rejoin his family after his studies and
be a scientist in his homeland.
Simple plans, but they were complicated by Mao
Tse-tung and the communist revolution.
"This is a long, long stoiy, a bloody stoiy," Hsu
said. Mao was purging geneticists and other scientists,
so Hsu stayed in the United States and attempted to
secure permission for his wife and daughter to immigrate. He finally succeeded in 1954, when his daughter was six years old. Because she was born shortly
after he had left for Austin, it was the first time he saw
her. During those years, he had been recruited by R
Lee Clark, M.D., founder of The University of Texas

How the bleomycin assay works
• Peripheral blood is collected and cultured.
• After three days of culture, bleomycin is
added.
• Five hours later, Colcemid is added to
induce mitotic arrest.
• Cells are haivested, treated with a hypotonic
solution, and placed on slides.
• Slides are stained so that chromosomes can
be visualized.
• Chromosome defects are counted.

M. D. Anderson Cancer Center. Hsu came to the
institution in 1955, where he is today.

New assay may help identify patients at risk
Hsu's achievements over the years are considerable
(see box, p. 4). His latest discovery-an assay designed to identify patients at risk for environmentally
caused cancer-may eventually prove to be an important component of cancer prevention programs. Hsu,
professor emeritus in the Department of Cell Biology
at M. D. Anderson Cancer Center, developed the
assay in collaboration with Lorraine M. Cherry, Ph.D.,
now at The University of Texas Health Science Center at Houston.
The genesis ofHsu's assay began over 10 years ago,
when he wondered, as had a few others in his field,
whether carcinogen sensitivity varied in the human
population. What distinguished Hsu from his colleagues
was that he intended to develop a system to test this
question formally. The task wasn't so easy. Fortunately, Hsu had one advantage other scientists didn't:
cooperative clinical colleagues who would help him
obtain human tissues and cells, both normal and tumorous. Hsu knew that if he was successful in developing the assay, access to such tissues would be essential to test the assay's validity.

Lab to Clinic

T. C. Hsu is professor
emeritus in the
Department of
Cell Biology. In 1991, he
was awarded the Medal of
Honor from the American
Cancer Society

Assay identifies susceptibility to chromos~me
damage
It took Hsu and his colleagues two years to perfect
what was to be called the bleomycin mutagen sensitivity assay; the assay quantitates the mutagenic effects (as
determined by chromosome defects) in lymphocytes
after bleomycin treatment. He had chosen the radiomimetic drug bleomycin because it induces DNA damage by a mechanism similar to that ofionizing radiation.
With the help of his clinical colleagues, Hsu began
collecting lymphocyte samples from healthy donors
(including asymptomatic smokers) and patients who
had tumors of the lung, colon, head and neck, or
breast. It took years to collect enough samples, but in
1989 Hsu reported some promising results: Lymphocytes from patients with lung, colon, or head and neck
cancer, generally considered to be environmentally
continued on page 4
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"I was often told
that the assay wouldn't work~
•
caused diseases, showed a significantly higher sensitivity to bleomycin than did cells from normal donors,
whereas patients with breast cancer, whose cause is
considered hereditary and hormone related, showed
no such sensitivity.
Hsu also compared "old smokers" (~ age 50) and
''young smokers" ( < age 50 ). If sensitivity to bleomycin
indeed was an indicator of susceptibility to cancer, he
surmised that asymptomatic old smokers would be
less sensitive, the rationale being that if they had smoked
for a long time and yet showed no sign of disease,
they may have some inherent resistance to carcinogens. Such was the case. Lymphocytes from old smokers were less sensitive to bleomycin than those from
young smokers and normal controls, the latter two
groups showing about the same level of sensitivity.
These results were encouraging. The difference in
sensitivity between patients with environmentally caused
and hereditary cancers and between old and young

smokers suggested that inherent sensitivity played some
role in cancer incidence, but Hsu and his coworkers
realized that the study demonstrated only the plausibility of their hypothesis. First, the distinction between
"environmentally caused" and "hereditary" cancers is
essentially a working hypothesis. Although much evidence supports this general distinction, the subtypes
of these cancers are biologically heterogeneous, so the
"distinction" could not be confidently used as a basis
for hard conclusions. Second, healthy donors were
studied separately from cancer patients. A better method
would be a prospective randomized trial of just one
group monitored over time. H su's objective, then,
was to identify a population, test its members'
bleomycin sensitivity, and then monitor subsequent
cancer incidence. These studies would help determine
whether bleomycin sensitivity could be used as a predictor of cancer risk.
Hsu turned to Stimson P. Schantz, M.D ., with his

Hsu's first major discovery: the hypotonic solution*

T

HERE IS ONE COMMON

thread in the 40-year career of T. C. Hsu (pronounced "Shoo"): the

hypotonic solution. First discovered by Hsu in 1952, this solution is now routinely used by
cytogeneticists to visualize and count mammalian chromosomes. In fact, the use of a hypotonic solution
is a standard step in Hsu's latest discovery, the bleomycin assay. The discovery of the hypotonic solution,
however, is a classic example of how serendipity, followed by hard work, can lead to m ajor advances. In
1952, Hsu was a postdoctoral fellow at The University of Texas Medical Branch in Galveston. Hsu had
received his doctorate in fruit fly (Drosophila) genetics, but at Galveston he was studying human and
mammalian cells. Hsu therefore spent his initial months learning new techniques and procedures. While
doing so, he stumbled on "a miracle."
When examining spleen cells under a microscope, Hsu noticed "beautifully scattered chromosomes .... I could not believe my eyes," he recalled. But he couldn't repeat the effect. He spent the next
four months modifying the cell preparation process. Finally, he duplicated the chromosome spread effect
by using a hypotonic solution instead of the balanced salt solution that was typically used in his

laboratory. Apparently, the earlier "miracle" was caused by a technician who had incorrectly prepared a
batch of standard salt solution, inadvertently making it hypotonic. And who was that technician? According to Hsu, no one knows. "No one admitted to committing an error."
*Quotes and background information were derived from Human and Mammalian Cytogenetics: An
Historical Perspective, by T. C. Hsu. New York: Springer Verlag, 1979, pp. 15-19.
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"Well, one idea begets
another, and you want to see
what happens~
•
idea. "If not for D r. Schantz, if not for his enthusiasm
and push, I probably would have published my paper
and then let it go," Hsu said . "He really took a personal interest in this and saw an opportunity to study
second primary tumors in head and neck cancer patients. Typically, after removal of the primary tumor,
about 20% of these patients develop another primary
tumor within five years." (Schantz, formerly of the
Department of H ead and Neck Surgery, now works
at Memorial Sloan-Kettering Cancer Center; he and
Hsu continue to collaborate.)
This, then, was a suitable patient population in which
to correlate sensitivity and incidence. Hsu, Schantz,
and their team enrolled 84 patients in the study, all of
whom were assessed for bleomycin sensitivity and life
style habits that exposed the subject to carcinogens
(e.g., smoking). All received definitive therapy for the
primary tumor. Of the 33 patients that the study team
classified as "hypersensitive" to bleomycin, nine (27.3%)
subsequently developed second primary tumors,
whereas of the 51 less-sensitive patients, only four
(7.8%) developed a second primary tumor.

Assay attracts worldwide interest
Ever the cautious scientist, Hsu is quick to say that
the study sample was too small for definitive conclusions; nevertheless, his results have spurred considerable interest worldwide. The University of Pittsburgh
is now conducting a similar study, and scientists from
the University of H awaii at Manoa, Free University
Hospital (Amsterdam), and Institut Armand-Frappier
(Quebec) have been sent to Hsu's laboratory to learn
the technique for the bleomycin assay. The current
______interesuemindslmn o£the days_When his idea wasn't
so eagerly received. "I was often told that the assay
wouldn't work," Hsu said. "Fortunately, many of my
clinical colleagues weren't so negative. They gave me a
great deal of encouragement and help."
One of those colleagues was Margaret R Spitz,
M.D., acting chairperson, Department of Epidemiology. She has used the bleomycin assay to study the
risks of tobacco and alcohol use in head and neck
cancer patients. "She has found that the risk estimate
increases with increasing consumption of these two
substances, but it escalates dramatically in individuals
who are also bleomycin sensitive," Hsu said. This as-

say is also being used in Spitz's study oflung cancer in
minority populations.
In other areas, Hsu has joined Waun Ki Hong,
M.D., chairman, Department of Head, Neck, and
Thoracic Medical Oncology, in a cancer prevention
program, and Hsu is looking for a dermatologist to
help him with his melanoma study. In the latter case,
Hsu will attempt to develop a new assay using 4nitroquinolone, which mimics the mutagenic properties of ultraviolet light.
This degree of collaboration is considerable for a
man who ostensibly retired in 1977. "Well," he said,
"one idea begets another, and you want to see what
happens." Hsu is grateful to the institution and the
University Cancer Foundation for continuing to fund
some of his research and administrative support since
1977. He works six hours a day and does his reading
and writing at home at night, except on Mondays
during football season. "I like Monday night football," he added. (His favorite team is the Houston
Oilers, though he's also a fan of Jim Kelly and the
Buffalo Bills.)
At times, though, Hsu recognizes that time will
eventually overtake him. Because many of these studies require long-term follow-up, Hsu thinks his melanoma studies will be his "swan song." But he's not
complaining. "I've been a lucky guy," he said. "All
my life, wherever I went, people bent over backwards
to help me. Since I came to this country, everyone has
been nice to me-well, except once a cab driver in
Boston called me a 'damn confederate'-but that's

it."
If the power of Hsu's ideas and playful humor are
evidence of the life force within_him, one_belieYes_he
will be around well into the next century, spending his
nights with science, poetry, or football. ■
-KEvrN FLYNN
Physicians who desire additional information may
write Dr. Hsu at the Department of Cell Biology,
Box 181, The University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Blvd., Houston,
Texas 77030, or call (713) 792-2582.
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Cryosurgery
continued from page 8
as effective as radiation therapy in achieving tumor
response.
"The use of cryotherapy is not new," said Johnson.
"What is new is freezing with minimal risk to the
patient-using ultrasound and multiple small probes
as opposed to one big one." The new technique was
refined in 1991 by radiologist Gary Onik, M.D., and
urologist Jeffrey Cohen, M.D., of Allegheny General
Hospital in Pittsburgh, Pennsylvania. Using real-time
transrectal ultrasound, they determined how to monitor the rate and location of prostate freezing. Last year
Cohen, who had been a fellow at M. D. Anderson 10
years ago, presented the approach to his former colleagues.
''We were excited that this could represent a new
local modality," said Andrew C. von Eschenbach,
M.D ., chairman of M. D. Anderson's Department of
Urology. M. D. Anderson became the second institution in the country to obtain a prostate ciyotherapy
device.
M. D. Anderson urologists decided to begin offering ultrasound-guided cryosurgery to patients with
recurrent disease in the prostatic or periprostatic area.

Figure 1 . Schematic of
ultrasound-guided
cryosurgery for
prostate cancer

Urethral warming
device

Cryoprobes in
prostate gland
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Patients eligible for the pilot study, which began last
July, had received radiation therapy as primary or definitive treatment, had no evidence of metastatic disease, and gave informed consent.
In 1992, 31 such patients underwent ultrasoundguided cryosurgery at M. D. Anderson. Because no
major complications have occurred in them or in the
more than 100 patients who have been treated at
Allegheny General Hospital, the procedure is now a
standard option for M. D. Anderson patients with
recurrent disease. (Medicare, however, still considers
cryosurgery for treatment of prostatic carcinoma investigational.)
M. D. Anderson chose this patient population for
its pilot study because the traditional treatment options for them either do not remove the tumor or
have undesirable side effects. Because the tissue is already damaged from radiation therapy, salvage
prostatectomy involves excessive risk of complications,
and surgeons often are not able to remove all the
tumorous tissue. "And further radiation therapy is usu ally out of the question because patients have had
about as much as the body can tolerate in that area,"
Johnson said. Until now these patients have had only
two choices: no therapy until symptoms appear or
hormonal therapy.
Hormonal therapy involves castration or costly in-
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jections every month over a period of time. In con-trast, cryosurgery is one-time therapy, and patients
resume normal activities in four to five days. Whereas
hormonal therapy only attempts to slow the growth
of the cancer, the goal of cryosurgery is to eradicate
the disease.

-

Controlled freezing using real-time ultrasound
Because cryosurgery is minimally invasive, it holds
promise for patients who cannot undergo radical surgery. Another advantage is that cryosurgery can be
repeated if the tumor does recur. The procedure takes
only about two hours.
The patient is placed under general anesthesia, and
the scrotum is tacked to the abdomen. By cystoscopy,
the surgeons first ensure that the cancer has not spread
to the urinary bladder. A catheter is inserted through
a suprapubic incision into the bladder to drain urine
during the surgery and afterward. A urethral warming
device is inserted into the bladder; warm, sterile water
circulates through this catheter to keep the urethra
from freezing.
An ultrasound transducer placed in the rectum enables surgeons to detennine the size of the prostate
and the number of cryoprobes needed. Three probes
are used in small prostates (under 15 g), and four or
five probes may be used in larger glands. "It is assumed based on some studies that one gets a sphere
of freezing that measures about 2 .8 cm in diameter
with each of the probes," Johnson said. "So the probes
are placed so that the spheres overlap, ensuring that
the entire prostate is frozen."
Using the ultrasound monitor, the surgeon can see
the prostate and the tumor and can guide the placement of the probes. Each probe is placed by inserting
a needle through the perineum into the prostate, passing a guide wire through the needle, and then sliding
a 3-mm dilator over the guide wire into the gland.
The dilator has a sheath that remains in place when
the dilator is removed. The cryoprobe is inserted into
the sheath, and the sheath is pulled back, leaving just
the robe within the rostate. At this int the robe
is fixed in place by cooling it to -70°C.
When all the cryoprobes are in place, the surgeon
lowers the temperature of the probes, which are filled
with liquid nitrogen, to -175°C to -200°C. As the
tissue freezes and hardens, its acoustic properties
change, so the progress can be monitored by
ultrasound (Figure 1). "The tissue turns dark black,"
Johnson said. ''You can see an ice ball forming."
The rectum is examined periodically to make sure it
isn't freezing. After about 10 to 15 minutes, the ice
ball reaches the capsule of the prostate, and the
cryomachine is turned off. When the probes thaw,

~ ~--£-=-~ ~~
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they are removed, and the quarter-inch incisions are
closed. "The patient is usually discharged the next
morning," Johnson said.
Because the prostate swells after cryosurgery, urination is difficult at first. The suprapubic catheter is left in
place until the patient begins voiding, usually three
days to a week later. It can be removed by his local
physician. Periodic follow-up evaluations include digital rectal examination, urinalysis, PSA analysis,
uroflowmetry, a quality-of-life questionnaire, prostatic
ultrasound, and selected site biopsies.

Research program to focus on ~ue and cellular
reactions to free-zing
Von Eschenbach will present initial results of the
pilot study at the annual meeting of the American
Urological Association in May. In early 1993, M. D.
Anderson will begin a research program on strategies
for maximizing the killing effect of the freezing. For
example, longer freezing times or multiple cycles of
freezing and defrosting may be more effective. ''We
hope to determine more accurately the freezing process and its effect on both normal and malignant cells,"
Johnson said. "There really has been very little work
published on what happens at the tissue level." He
hopes to determine the answers to several questions. If
the cryoprobe temperature is -200°C, what is the temperature in the surrounding tissue? Are malignant cells
more sensitive to freezing than normal cells? Which
elements of the prostate are more apt to be destroyed?
Is the connective tissue component more resistant to
freezing than the glandular element? How does the
body "absorb" the dead tissue after cryosurgery?
Follow-up of the patients being treated now for
recurrent disease will demonstrate how effectively
cryosurgery eradicates prostatic carcinoma. "Ifit works
in this situation, and we can prove that over the next
two or three years, then we can consider it in selected
patients for primary therapy, instead of surgery or radiation," Johnson said. Taking into account the operation time, length of hospitalization (about seven
da s and len
of recove four to five weeks for
radical prostatectomy, cryosurgery is cheaper. "It certainly would have a significant impact on the cost of
care in this country if it can be proven to be useful,"
Johnson said. ■
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Cryosurgery for prostate cancer shows
promise in pilot study
Treatment Update

Douglas E. Johnson is a
professor of urology in the
Department of Urology

With traditional therapies, prostate cancer patients face two depressing prospects: a long treatment or recovery period and a high risk of severe
complications such as impotence and incontinence.
But with a new experimental technique-ultrasoundguided cryosurgery-patients are hospitalized for
only two days, and the risk of complications is low,
according to urologists at The University of Texas
M. D. Anderson Cancer Center.
Prostatic carcinoma is the most common cancer in
American men; 132,000 cases are diagnosed a year.
New screening procedures, such as prostate-specific
antigen (PSA) tests and ultrasound-guided biopsies,
are detecting an increasing number of cases.
"From 1972 to 1988, we averaged six radical
prostatectomies a year," said M. D. Anderson Cancer
Center urologist Douglas E. Johnson, M.D. ''We're
doing 150 this year."
Given this increase, the development of an effective
yet minimally traumatic treatment has become all the
more important. To achieve this goal, two common

technologies, ultrasound and
combined in a new wa .

cry

urg ry ha

oo n

New technique makes old idea feasible
When Johnson j in d th M. D. And rson facul
25 years ago, hormonal th rap was used primary
treatment for most pati nts with pri ta.ti carcin m
and radiation the
was ·usr be · · t be used.
Around this time, in estigators first
n i d th t
cryosurgery, which was commonl mpl
lignancies in the skin, e es and c rvix could be applied in the prostate.
In early attempts, the ayoprobe was inserted through
the penis, freezing and destroying the ur thra which
resulted in patients passing blood and tisrue for weeks
or months. E en after an open perinea! approach was
developed, urethra damage and urethrocut:aneous or
urethrorectal ~ a formation often occurred because
the freezing could not be monitored. e ertheless
researchers were encouraged because cryosurgery appeared to be as effective as prostatectom and almost
continued on page 6

